Literature DB >> 22331936

The challenge of choosing appropriate end points in single-arm phase II studies of rare diseases.

Stefan Sleijfer, Andrew J Wagner.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 22331936     DOI： 10.1200/JCO.2011.40.6942

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

1.  An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma.

Authors:  Andrew C Nelson; Nischalan Pillay; Stephen Henderson; Nadège Presneau; Roberto Tirabosco; Dina Halai; Fitim Berisha; Paul Flicek; Derek L Stemple; Claudio D Stern; Fiona C Wardle; Adrienne M Flanagan
Journal:  J Pathol       Date:  2012-09-26       Impact factor: 7.996

2.  Time to progression ratio in cancer patients enrolled in early phase clinical trials: time for new guidelines?

Authors:  Sarah Watson; Jessica Menis; Capucine Baldini; Patricia Martin-Romano; Jean-Marie Michot; Antoine Hollebecque; Jean-Pierre Armand; Christophe Massard; Jean-Charles Soria; Sophie Postel-Vinay; Xavier Paoletti
Journal:  Br J Cancer       Date:  2018-10-17       Impact factor: 7.640

Review 3.  The Challenges of Clinical Research in Rare Cancers: Bevacizumab Use in Low-Grade Serous Ovarian and Primary Peritoneal Cancers.

Authors:  Carolyn Grande; Constance Visovsky; Marcia S Brose
Journal:  J Adv Pract Oncol       Date:  2017-05-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.